Product Description
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Protocol 20020168 | P2 |
Completed |
Parkinson's Disease |
2005-11-01 |
|
| NCT00115427 | P1 |
Completed |
Parkinson's Disease |
None |